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Abstract: 
Mannose-binding lectin (MBL) is a circulating protein that acts as a soluble 
pattern recognition molecule of the innate immunity. It binds to 
carbohydrate patterns on the surface of pathogens or of “altered cells”, 
with activation of the lectin pathway of the complement system.  Recent 
evidence indicates that MBL contributes to the pathophysiology of 
ischemia-reperfusion injury and other conditions. Thus, MBL inhibitors offer 
promising therapeutic strategies, since they prevent preventing the 
interaction of MBL with its target sugar arrays. We developed and 
characterized a novel assay based on surface plasmon resonance for in 
vitro screening of these compounds, which may be useful before the more 
expensive and time-consuming in vivo studies. The assay measures the 
inhibitor’s ability to interfere with the binding of murine MBL-A or MBL-C, 
or of human recombinant MBL, to mannose residues immobilized on the 
sensor chip surface. We have applied the assay to measure the IC50 of 
synthetic glycodendrimers, two of them with neuroprotective properties in 
animal models of MBL-mediated injuries.   
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ABSTRACT 
 
Mannose-binding lectin (MBL) is a circulating protein that acts as a soluble pattern 
recognition molecule of the innate immunity. It binds to carbohydrate patterns on the surface 
of pathogens or of “altered cells”, with activation of the lectin pathway of the complement 
system.  Recent evidence indicates that MBL contributes to the pathophysiology of ischemia-
reperfusion injury and other conditions. Thus, MBL inhibitors offer promising therapeutic 
strategies, since they prevent preventing the interaction of MBL with its target sugar arrays. 
We developed and characterized a novel assay based on surface plasmon resonance for in 
vitro screening of these compounds, which may be useful before the more expensive and 
time-consuming in vivo studies. The assay measures the inhibitor’s ability to interfere with 
the binding of murine MBL-A or MBL-C, or of human recombinant MBL, to mannose 
residues immobilized on the sensor chip surface. We have applied the assay to measure the 
IC50 of synthetic glycodendrimers, two of them with neuroprotective properties in animal 
models of MBL-mediated injuries.   
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Introduction 
Mannose binding lectin (MBL)  is a calcium-dependent (C-type) lectin, belonging  to the 
collectin family, with an important role in innate immunity 1. MBL circulates in blood 
complexed with MBL-serine proteases (MASPs) and acts as a soluble pattern recognition 
receptor, binding specific carbohydrate patterns exposed on the surface of pathogens or of 
“altered-self” cells through its carbohydrate-recognition domain (CRD). On binding the 
target cells, MASPs are activated, initiating the lectin pathway (LP) of the complement 
system.  
MBL has been implicated in experimental models of myocardial 2, renal 3 and 
gastrointestinal injury 4, cerebral ischemia/reperfusion injury 5, 6 and traumatic brain injury 7, 8 
as well as pre-eclampsia 9. In all these conditions, MBL  appears to contribute to tissue injury 
and its deletion or inhibition is protective. MBL inhibitors might therefore be as promising 
therapeutic strategies, and reliable in vitro assays are needed to identify them, before more 
expensive and time-consuming in vivo studies. 
 MBL-binding properties of compounds can be investigated by a direct surface plasmon 
resonance (SPR) assay in which unlabeled putative MBL ligands are flowed onto 
recombinant MBL  immobilized on the sensor chip 5. Binding is revealed in real time as a 
change of mass at the surface, and the interaction can be characterized in terms of on and off 
rates (kinetics) and binding strength 10.  Although this approach is fairly straightforward and 
useful for initial screening purposes, it suffers some limitations: MBL can be bound on a site 
different from CRD, so it may not result in inhibitory activity; binding affinities can be 
overestimated due to multivalent interactions; immobilization procedures can alter the 
binding properties of MBL. We experienced difficulties in immobilizing recombinant murine 
MBL-C (mMBL-C, one of the two murine isoforms, together with mMBL-A 11). Then, last 
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but not least, immobilization of MBL on a surface makes this configuration different from the 
physiological condition. 
We have now developed and characterized a novel SPR-based assay that allows in vitro 
identification of MBL inhibitors, with a design that closely mimics real conditions, since the 
compound’s effects are measured by their ability to inhibit MBL binding to mannose residues 
exposed on the (sensor) surface.  Thus, this approach can assess the inhibition of a property 
of MBL which is relevant to its functional activity. The assay is suited to study the inhibition 
of native plasmatic mMBL-A and mMBLC, and of recombinant human MBL (rhMBL). We 
used it to measure the inhibitory effects of synthetic polymannosylated glycodendrimers, two 
of them – Polyman2 and Polyman9   –  with protective properties in animal models of MBL-
mediated injuries 5, 8, 9. 
 
Materials and Methods 
Animals 
Plasma was obtained from eight-week-old C57Bl/6 mice (wild-type, WT, 20-25g; Harlan 
Laboratories) and from C57Bl/6 mice with a target mutation of both MBL-A and MBL-C 
genes (MBL-/-, 20-25g, purchased from Jackson Laboratories-USA and colonized at the 
Mario Negri Institute). Briefly, blood samples were collected from the vena cava in 10 mM 
ethylendiaminetetracetic acid and 0.125% polybrene (Sigma-Aldrich). Plasma was separated 
by centrifugation at 2000 g at 4°C for 15 min, immediately stored and kept at -80°C until use. 
The IRCCS-Istituto di Ricerche Farmacologiche Mario Negri adheres to the principles set out 
in the following laws, regulations, and policies governing the care and use of laboratory 
animals: Italian Governing Law (D.lgs 26/2014; Authorisation n.19/2008-A issued March 6, 
2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies providing 
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internal authorisation for those conducting animal experiments (Quality Management System 
Certificate – UNI EN ISO 9001:2008 – Reg. No. 6121); the NIH Guide for the Care and Use 
of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council 
Directive 2010/63/UE). The Statement of Compliance (Assurance) with the Public Health 
Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently 
reviewed (9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance 
#A5023-01). The studies reported here were within a project specifically authorized by the 
Italian Ministry of Health (Decree n° 161/2014B).  
 
SPR-based assay 
SPR is a powerful label-free method widely used to study binding between two 
macromolecules 12. Typically, one of the interacting partners is immobilized on a sensor chip 
surface and the other is flowed through a microfluidic system in contact with the chip surface. 
Binding is revealed in real time as a change of mass at the surface. Although the most 
common application of SPR instruments is to determine affinity parameters for biomolecular 
interactions 10, its versatility permits many other uses, including label-free immunoassays 13-
15
. 
The novel assay described here involves several steps. Fig. 1 summarizes the four steps 
required for studies with murine plasma (two mMBL isoforms); studies with rhMBL are 
limited to the first two steps.  The first step is the covalent immobilization of mannosylated 
bovine serum albumin (Man-BSA, Dextra Laboratories, Reading, UK) on the sensor chip 
(GLC, Bio-Rad) using amine coupling chemistry 16. Thus, Man-BSA molecules  are bound to 
the sensor surface through the protein moieties leaving the mannose residues exposed. The 
ProteOn XPR36 Protein Interaction Array system (Bio-Rad Laboratories, Hercules, CA) used 
Page 6 of 25
http://mc.manuscriptcentral.com/jbsc
Journal of Biomolecular Screening
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
for these SPR studies, has six parallel flow channels that can immobilize up to six ligands on 
the same sensor chip.  In parallel to Man-BSA we always immobilized BSA (Sigma ) as 
reference.  Immobilization levels were about 3000 and 4000 resonance units (RU, 1 RU 1 pg 
protein/mm2). After the first immobilization step, the ProteOn XPR36 fluidic system is 
rotated 90° 17 so that up to six different solutions can be injected simultaneously over the 
immobilized ligands (Fig. 1).  In this second step, we injected MBL-containing solutions, 
preincubated with or without the inhibitors (see below).  We used mouse and human plasma, 
diluted (as indicated) in 10 mM running buffer (TRIS buffer containing 150 mM NaCl and 
0.005% Tween 20, pH 7.4 , plus 1.2 mM CaCl2); or running buffer with rhMBL added (R&D 
Systems, Minneapolis, MN). This second step aims to capture MBL (mMBL isoforms or 
rhMBL) on the Man-BSA surface.  The mannose-dependent SPR binding signal is obtained 
by subtracting the mannose-independent nonspecific response on the reference surface (BSA 
only). The following steps are carried out after further rotation of the fluidic system (Fig. 1) 
and regards the sequential injections of anti-MBL antibodies.  After injecting murine plasma 
we injected 10 µg/mL anti-mMBL-A and 10 µg/mL anti-mMBL-C antibodies (Hycult 
Biotech, The Netherlands) to specifically recognize and quantify the isoform captured during 
the second step (Fig. 1).  Two anti-hMBL antibodies were tested after injection of human 
plasma: 10 µg/mL anti-hMBL antibody 3E7 (Hycult Biotech, The Netherlands) and 10 µg/ml 
anti-hMBL antibody 3B6 (Abcam, Cambridge, UK). All SPR assays were run at 25°C. The 
sensorgrams (time course of the SPR signal in RU) were normalized to a base-line of 0.  
For the analysis of putative MBL inhibitors, diluted plasma or running buffer spiked with 
rhMBL were preincubated for 30 min at 25°C, with or without glycodendrimers at different 
concentrations and then flowed onto immobilized Man-BSA and BSA (Fig 1, step 2).  The 
six parallel flow channels meant we could analyze the effect of up to four concentrations 
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simultaneously, leaving one for mouse plasma preincubated with vehicle alone (total binding, 
TB) and one channel for MBL-/- mouse plasma (non-specific binding, NSB).  The SPR 
binding signal at t=100 s,  in the presence of each drug concentration (BD), was used to 
calculate the percentage inhibition of specific binding (%INH-SB) as follows: 
%INH-SB = ((TB – BD) / (TB-NSB)) *100 
The aim of these studies was to identify compounds that prevent the MBL interaction with 
mannose residues and to determine their potency, i.e. the concentration inhibiting MBL 
binding by 50% (IC50). 
 
Synthetic polymannosylated glycodendrimers 
The glycodendrimers we tested as MBL inhibitors are shown in Fig. 2.  They are Polyman2 
(also referred to as Dendron 12 18 which is a tetravalent glycodendron carrying a pseudo-
trimannoside headgroup; Polyman9, a hexavalent glycodendrimer with a flexible core, 
carrying a pseudo-dimannoside headgroup (also referred to as glycodendrimer 13.3 19) and 
Polyman31, a hexavalent glycodendron carrying the same pseudo-dimannoside headgroup on 
a rigid-core architecture 20. The synthesis and characterization of the compounds we used has 
been described previously 18-20. 
 
 
Results 
Characterization of the SPR assay for mMBL-A and mMBL-C 
Diluted plasma from WT mice injected over a sensor surface coated with Man-BSA resulted 
in a marked SPR signal (2550 and 1500 RU, on average, at plasma dilutions of 1:50 and 
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1:100 respectively), much higher than in a parallel reference surface coated with BSA only 
(800 RU and 530 RU) (representative sensorgrams in Fig. S1A).  This indicated the presence 
of a mannose-dependent binding signal, highlighted in sensorgrams obtained by subtracting 
the signal in the reference surface (Fig. S1B and Fig. 3A).  Most of this specific signal was 
due to mMBL, since plasma from MBL-/- mice gave a much lower specific signal, only 
20±11 % of the WT plasma value  (mean±SD, n=18)  (Fig. 3A, Fig. S1B).   
The binding of plasmatic mMBL to immobilized mannose residues was very stable as 
shown by the low dissociation rates after the injections (Fig. 3A) thus allowing sequential 
injection of the antibodies against mMBL-A and mMBL-C.  These injections resulted in clear 
SPR binding signals (Fig. 3B-C) indicating that both murine isoforms were actually captured 
during the plasma injection; much lower signals were observed in the surfaces where plasma 
from MBL-/- had been flowed (23±16 % and 11±13 % with antibodies against mMBL-A and 
mMBL-C, mean±SD, n=18), thus confirming the specificity of the measured signal. The SPR 
signal with the anti-mMBL-A antibody was linear during the injection period whereas a 
plateau was reached  during the injection of the anti-mMBL-C antibody.  This indicates a 
higher association rate constant of the anti-mMBL-C then the anti-mMBL-A antibody, and 
that less mMBL-C than mMBL-A was captured by mannose. 
As expected, the binding signals due to both mMBL-A and mMBL-C correlated with 
plasma dilution (Fig. S2A-B), although there was a tendency to saturation with the highest 
concentrations (1:50 and 1:25).  The IC50 was determined using plasma diluted at either 1:50 
or 1:100, with no significant differences in the results.   
Preincubation of plasma with different concentrations of mannose resulted in 
concentration-dependent inhibition of both mMBL-A and mMBL-C binding to immobilized 
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mannose, as indicated by the subsequent injections of the corresponding antibodies. The IC50 
was similar for the two isoforms, respectively 5.4 and 5.2 mM for mMBL-A and mMBL-C. 
 
Characterization of the assay for hMBL 
Injection of diluted human plasma over immobilized Man-BSA resulted in a marked SPR 
signal (400 RU on average, at plasma dilutions of 1:50), much higher than that observed in a 
parallel reference surface coated with BSA only (50 RU) (representative sensorgrams in Fig. 
S1C).  This indicated the presence of a mannose-dependent binding signal (i.e. obtained by 
subtraction of the signal in the reference surface), although this was much lower than with 
murine plasma (Fig. S1D vs Fig. S1B). 
Despite the presence of a mannose-dependent binding signal, we were not able to 
confirm the capture of hMBL with anti-hMBL antibodies.  Results were negative with two 
different anti-hMBL antibodies, at concentrations up to 10 µg/mL, even when plasma was 
only diluted 1:10 (data not shown).  To overcome this problem, we developed a different 
approach testing the compounds for their ability to inhibit the binding of rhMBL to 
immobilized mannose. Different concentrations of rhMBL (Fig S2C), diluted in running 
buffer, resulted in a concentration-dependent binding signal, linear in the 0.5-8 nM range 
(Fig. S2D).  Global fitting of these sensorgrams according to the simplest 1:1 interaction 
model (Langmuir model) gave an estimated  KD of 1 nM.   
 
Inhibitory effects of polymannosylated glycodendrimers 
Polyman2 inhibited the binding of mMBL-A and mMBL-C to immobilized mannose with 
similar IC50 values (93 and 84 µM, Fig. 4A-B) whereas Polyman31 was highly selective for 
Page 10 of 25
http://mc.manuscriptcentral.com/jbsc
Journal of Biomolecular Screening
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
the two isoforms, inhibiting mMBL-C with a very low IC50 (0.5 µM) but being much less 
active on mMBL-A (IC50>200 µM) (Fig. 4A-B).  Polyman9 also had a lower IC50 on mMBL-
C (65 µM) than on mMBL-A (IC50>200 µM) (Fig. 4A-B 8).   
As an example of raw data, Fig. S3A shows representative sensorgrams obtained 
injecting of plasma preincubated or not with 3 µM Polyman31, in parallel with plasma from 
MBL-/- mice.  At this concentration, Polyman31 had no effect on MBL-A binding (Fig. 
S3B), but it reduced MBL-C binding by 85% (Fig. S3C).  The 20% decrease during the 
plasma injection (Fig. S3A) indicated that most (~ 77%) of the MBL captured by mannose 
was accounted for by MBL-A.  
Preincubation of rhMBL (8 nM) with different concentrations of dendrimers resulted in 
dose-dependent inhibition of rhMBL binding to immobilized mannose (Fig. 4C).  In this 
assay Polyman31 was the most potent inhibitor (IC-50 62 µM), followed by Polyman9 (~ 136 
µM) and Polyman2 (~ 270 µM). 
 
Discussion  
We report the characterization of a novel SPR assay for in vitro screening of MBL inhibitors, 
analyzed for their ability to interfere with MBL binding to carbohydrate patterns.   This was 
achieved by flowing MBL-containing solutions, with or without inhibitors, over a sensor chip 
exposing mannose residues.   
The mannose-dependent SPR signal with diluted murine plasma is mostly (80% on 
average) due to mMBL, as indicated by the results with plasma of MBL-/- mice. This binding 
has a very low dissociation rate, as expected for multivalent binding, so permitting 
subsequent injections of antibodies against mMBL-A and mMBL-C  to specifically recognize 
and quantify the isoform captured by mannose. In our conditions 70-80% of the mMBL-
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dependent SPR signal is accounted for by mMBL-A, although its serum levels in C57Bl/6 
mice are  4-5 times lower than those of mMBL-C 21, 22. Since the molecular mass of the two 
isoforms is comparable 21, this suggests that mMBL-A has greater affinity than mMBL-C for 
immobilized mannose. However, the smaller proportion of mMBL-C captured by 
immobilized mannose is compensated by the higher affinity of the corresponding antibody.  
Thus, the SPR signal 100 sec after injection of the anti-mMBL-C antibody was similar, on 
average, to that seen 100 sec after injection of the anti-mMBL-A antibody. 
The SPR data obtained injecting diluted human plasma indicated a mannose-dependent 
binding signal which, however could not be definitely associated to the capture of hMBL. In 
fact, there was no SPR signal on subsequent injection of  anti-hMBL antibodies.  Possibly the 
“mannose-dependent” binding signal after injection of human plasma is either: i) not due to 
hMBL capture or ii) actually due to hMBL, but the two anti-hMBL antibodies tested did not 
bind it efficiently enough for detection in our set-up. 
The mannose-dependent binding signal with human plasma was much lower (20%) than 
the signal with murine plasma, in agreement with the lower hMBL concentration (1-1.5 
µg/mL) 23, 24 than mMBL-A (8-20 µg/mL) or mMBL-C (30-100 µg/mL) 21, 22. Insufficient 
capture of hMBL on the sensor chip might thus contribute to the lack of measurable binding 
with anti-hMBL antibodies, although results were also negative using plasma or serum ten-
fold only diluted. Other factors required for an efficient SPR assay, and possibly not met with 
native hMBL, are: i) adequate  affinity of hMBL for the immobilized mannose residues, 
particularly an association rate constant permitting the capture of enough hMBL during the 
short association phase (few minutes), and/or ii) suitable affinity of the anti-hMBL antibodies 
employed for these studies. In this regard, successful detection of plasmatic mMBL-A is very 
likely due to its high affinity for immobilized mannose (higher than that of mMBL-C), 
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whereas successful detection of mMBL-C is probably likely due to the high serum 
concentrations and the high affinity of the anti-mMBL-C antibody (higher than that of anti-
mMBL-A antibody). 
To evaluate the effects of potential inhibitors on hMBL, we developed an SPR assay 
using rhMBL.  A suitable SPR binding signal was obtained by flowing 8 nM rhMBL, 
dissolved in buffer, over immobilized mannose residues (about 7 µg/mL, i.e. much higher 
than the concentration present in diluted human plasma), while lower concentrations gave 
proportionally lower SPR signals.  
We used these assays to study the inhibitory effects of synthetic polymannosylated 
glycodendrimers.  Native MBL is found as oligomers of a trimeric building block, with 
multiple CRD domains 25 which efficiently bind to carbohydrate patterns through multivalent 
protein-sugar interactions. Thus, to interfere with these, multivalent inhibitors such as 
glycodendrimers have been designed and studied over the past ten years as potential 
antagonists 26, 27.  Polyman2 18 is a tetravalent pseudo-trimannoside dendron which showed 
potent protective activity in mouse models of cerebral ischemia 5 or pre-eclampsia 9 where 
MBL significantly contributed to the injury.  Polyman9 is a hexavalent pseudo-dimannoside 
dendrimer based on a flexible scaffold 19 which showed neuroprotective effects in a murine 
model of traumatic brain injury 8. Polyman31 is a new hexavalent pseudo-dimannoside 
dendrimer based on a rigid-core architecture 20.  In our assay, Polyman2 showed no 
selectivity between mMBL-A and mMBL-C (IC50 93 and 84 µM) whereas Polyman-31 had a 
completely different interaction profile, being very potent on MBL-C (IC50 0.5 µM) but 
almost inactive on mMBL-A up to 200 µM. Polyman9 had a similar profile, inhibiting 
mMBL-C (IC50 65 µM) but not MBL-A (IC50 >>200 µM) 8. These molecules also inhibited 
rhMBL binding of to mannose residues with IC50 from 62-270  µM.  
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The inhibitor concentrations we used (µM range) greatly exceed those of MBL (nM 
range, in diluted murine plasma and rhMBL). Thus, the percentage inhibition of MBL 
binding to mannose is indicative of the occupancy of MBL proteins and the IC50 is a measure 
of the inhibitor’s affinity for MBL. The affinities of Polyman2 for mMBL-A and rhMBL 
(IC50 93 and ~270 µM) are higher than those measured by direct SPR assay, i.e. directly 
flowing the dendrimer over immobilized recombinant mMBL-A (KD 4.7 µM, data not 
shown), or rhMBL (KD 6 µM, 5).  A similar difference was reported for polymeric inhibitors 
of the lectin DC-SIGN using analogous SPR approaches 15 and is possibly due to a lower 
impact of avidity effects when interactions occur in solution. 
A mannan immunoassay has been described in which murine plasma was incubated on 
mannan-coated microtiter wells and murine MBL  isoforms were  then recognized  by 
biotinylated anti-MBL antibodies and europium-labeled streptavidin 21. This method was 
used to quantify mMBL-A and mMBL-C concentrations in mouse sera, but to the best of our 
knowledge it has never been used to screen MBL inhibitors. In comparison with our SPR 
assay, immunoassays in microtiter wells are probably more sensitive, due to signal 
amplification. However, the SPR assay has other worthwhile advantages: i)  it does not need 
any labeled reagent and takes less of the antibodies than for microtiter wells; ii)  the amount 
of bound anti-MBL antibody - and thus MBL - is immediately determined by SPR whereas  
further steps are required when using microtiter wells, e.g. incubation with europium-labeled 
streptavidin for immunofluorometric assay 21; iii) the long incubation of plasma in mannan-
coated microtiter wells may reduce the binding between the inhibitor and plasmatic MBL, 
due to the equilibrium shift induced by the high-affinity binding of free MBL to immobilized 
sugars; this potential artifact, leading to underestimation of the compound’s inhibitory effect, 
Page 14 of 25
http://mc.manuscriptcentral.com/jbsc
Journal of Biomolecular Screening
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
is probably absent during the very short flow of plasma over the mannose-coated SPR 
surface. 
In conclusion, we have extensively characterized a novel assay, convenient for in vitro 
screening of putative MBL inhibitors, to select the appropriate compounds for the more 
expensive and time-consuming in vivo studies.  This approach has been successfully used to 
identify a selective mMBL-C inhibitor, Polyman9, which conferred neurobehavioral 
protection when given shortly after traumatic brain injury 8. We also found another 
glycodendrimer, Polyman31, with even higher affinity and selectivity for mMBL-C. 
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Figure Legends 
 
Figure 1. Schematic summary of the surface plasmon resonance assay for inhibitors of 
murine MBL isoforms. 
 
Figure 2. Structures of the glycodendrons used in this study: Polyman2, Polyman9 and 
Polyman31. 
 
Figure 3. Capture of plasmatic mMBL-A and mMBL-C by immobilized mannose residues. 
A: representative sensorgrams (i.e. time course of SPR signal  in resonance units, RU) with 
plasma (1:50) from wild-type (WT) and MBL-/- (KO) mice injected over chip surfaces 
coated with mannosylated-BSA (Man-BSA).  These sensorgrams were obtained after 
subtraction of the non-specific signal measured on a parallel surface coated with BSA (see 
also Fig S1).  Plasma was injected for 10 min (bars). B-C: representative sensorgrams with 
sequential injections of anti-MBL-A or anti-MBL-C antibodies shortly after the injection of 
plasma. 
 
Figure 4. Inhibitory effect of dendrimeric compounds on mMBL-A (A), mMBL-C (B) or 
rhMBL (C) binding to mannose residues. Polyman31 is indicated in blu, Polyman2 in red, 
Polyman9 in green (data of Polyman9 from ref. 8). Each  value is the mean±SD of 2-3 
independent SPR sessions. 
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Figure 2 
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Figure S1
Raw sensorgrams after injection of murine and human plasma, and determination of the mannose-dependent binding signal. 
A,C : representative sensorgrams after injection of plasma from wild-type (WT) and MBL-/- (KO) mice, or human plasma over chip surfaces coated 
with mannosylated-BSA (Man-BSA) or BSA. Plasma (1:50)  was injected for 10 min (bars). B,D: normalized sensorgrams obtained after 
subtraction of the signal observed on the BSA-coated surfaces only.  This gives a mannose-dependent SPR binding signal
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Figure S2
Correlation between MBL concentration and SPR signal. 
A-B: the SPR signal due to mMBL-A and mMBL-C correlates with plasma dilution. SPR values i(n resonance units, RU)  were measured after 
injection of anti-mMBL-A or anti-mMBL-C antibodies. Data were fitted with a hyperbola equation.  C:  Sensorgrams obtained injecting different 
concentrations of recombinant human MBL (rhMBL) over chip surfaces coated with mannosylated-BSA.  rhMBL was injected for 2 min (bar). These 
sensorgrams were obtained after subtraction of the non-specific signal (even if negligible) measured on a parallel surface coated with BSA.  D: 
linearity between rhMBL concentration and SPR binding signal, measured 100 secs after injection of rhMBL-containing solutions.
Page 25 of 25
http://mc.manuscriptcentral.com/jbsc
Journal of Biomolecular Screening
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure S3
Raw sensorgrams showing the inhibitory effects of 3 µM 
Polyman31.
A: representative sensorgrams with injection of plasma 
from wild-type (WT) mice , incubated or not with 3 µM 
Polyman31, and from MBL-/- (KO) mice, over chip surfaces 
coated with mannosylated-BSA (Man-BSA).  Sensorgrams
were obtained after subtraction of the non-specific signal 
A
B
measured on a parallel surface coated with BSA (see also 
Fig S1).  Plasma (1:100) was injected for 10 min (bars). 
B-C: representative sensorgrams with sequential 2-min 
injections of anti-MBL-A or anti-MBL-C antibodies shortly 
after the injection of plasma.C
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